FORMULATION AND EVALUATION OF GLIMEPIRIDE 4 MG. SUSTAINED RELEASE TABLETS

The present study was aimed at the formulation and evaluation of Glimepiride 4 mg sustained release tablets to enhance therapeutic efficacy and improve patient compliance. Glimepiride, a third-generation sulfonylurea, is widely used in the treatment of Type 2 Diabetes Mellitus. Due to its short biological half-life and requirement for prolonged glycemic control, sustained release formulations were developed using hydrophilic polymers such as HPMC K100M and carbapol 934P. The SR- Tablets were prepared by wet granulation method and evaluated for pre-compression and post-compression parameters. And In-vitro dissolution studies were performed for 12 hours, and release kinetics were analyzed. The optimized formulation showed controlled drug release with good physicochemical properties, indicating suitability for sustained release therapy.